UCSF使用HP Bioprointer来优化癌症药物的组合

UCSF使用HP Bioprointer来优化癌症药物的组合

2020年3月23日,星期一,下午12:05

活动:HP Inc. |数字公平

内容:博客

加利福尼亚州帕洛阿尔托(Palo Alto),2020年3月23日 /欧宝体育官方f68点top 3BL媒体 / - 观看旧金山加州大学旧金山分校外科肿瘤学研究实验室主任戴维·唐纳(David Donner)博士,解释了创新的新微流体技术在癌症研究中的好处。

关于HP的微流体

惠普公司(HP Inc.to create the world’s largest digital printing company. All this provides the foundation to extend this technology into new domains. HP’s Specialty Printing Systems (SPS) and the Microfluidics Technology and Operations (MTO) teams have collaborated to bring HP’s first life science application in this space to market: The HP D300e BioPrinter with inkjet printing technology is enabling automated laboratory dispensing to “print” pharmaceutical samples instead of ink. The BioPrinter is being used by labs and pharmaceutical companies all over the world, including the Centers for Disease Control & Prevention (CDC) in the Antibiotic Resistance (AR) Lab Network, to perform antimicrobial susceptibility testing for health departments and hospitals nationwide. Learn more:http://www.hp.com/go/bioprint

关于HP Inc.

HP Inc.(NYSE:HPQ)创造了使每个人的生活更美好的技术。通过我们的个人系统,打印机和3D打印解决方案的产品和服务组合,我们设计了令人惊讶的经验。有关HP Inc.的更多信息可在www.hp.com

媒体联系
莱西·海恩斯(Lacey Haines)
lacey.haines@hp.com
http://press.ext.hp.com